SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001626199-23-000029
Filing Date
2023-01-26
Accepted
2023-01-26 16:13:54
Documents
13
Period of Report
2023-01-24
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alpn-20230124.htm   iXBRL 8-K 62648
2 EX-3.1 alpn-amendedandrestatedbyl.htm EX-3.1 159557
  Complete submission text file 0001626199-23-000029.txt   404652

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alpn-20230124.xsd EX-101.SCH 1951
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alpn-20230124_lab.xml EX-101.LAB 25850
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alpn-20230124_pre.xml EX-101.PRE 13617
7 EXTRACTED XBRL INSTANCE DOCUMENT alpn-20230124_htm.xml XML 11760
Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37449 | Film No.: 23557841
SIC: 2834 Pharmaceutical Preparations